Landmark pathogenesis

Hiebert et al.

The t(12;21) translocation converts AML-1b from an activator to a repressor transcription.
Mol Cell Biol April 1996; 16:1349-55.
Description: One of several articles demonstrating the biologic significance of the t(12;21) fusion protein in leukemogenesis.
PubMed citation number: 8657108.

Corral et al.

An All-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes.
Cell June 14, 1996; 85:853-61. .
Description: Article demonstrating biologic implications of MLL translocation in a murine model.
PubMed citation number: 8681380.

Landmark clinical diagnosis

Harris et al.

World Health Organization Classification of Neoplastic Disease of the Hematopoietic and lymphoid Tissues
Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia November, 1997.
Description: Details current WHO criteria for diagnosis of various leukemia/lymphoma subgroups.
PubMed citation numbers: 10577857.

Yeoh et al.

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
Cancer Cell March 2002; 1:133.
Description: One of several studies identifying the ability of gene expression profiling to identify prognostically important leukemia subtypes.
PubMed citation number: 12086872.

Landmark treatment

Kwak et al.

Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.
JCO June 1990; 8:963.
Description: Study demonstrating the importance of achieving target doses of chemotherapy as a significant predictor of survival.
PubMed citation number: 234830

Mora et al.

Lymphoblastic Lymphoma of Childhood and the LSA2-L2 protochol: the 30 year Experience at Memorial-Sloan-Kettering Cancer Center.
Cancer Sept 15, 2003; 98:1283-91.
Description: Study reporting long term survival and high rate of cure with chemotherapy alone for treatment of adult ALL.
PubMed citation number: 12973853.

Gayon et al.

Children’s Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.
Leukemia December 2000; 14:2223-33.
Description: Meta-analysis 16,000 children treated for ALL since 1983 identifying treatment factors associated with improved outcomes over that period.
PubMed citation number: 11187913.

Sweetenham et al.

High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group.
JCO June 1, 2001; 19:2927-36.
Description: Randomized trial exploring the potential benefit of dose intensification and autologous transplant in lymphoblastic lymphoma.
PubMed citation number: 11387366.

Cave et al.

Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia. European Organization for Research and Treatment of Cancer –Childhood Leukemia Cooperative Group.
NEJM August 27, 1998; 339:591-9.
Description: One of several studies identifying the clinical significance of molecular response by PCR as a predictor of relapse.
PubMed citation number: 9718378.

Pui et al.

Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia.
NEJM Aug 14, 2003; 349:640-9.
Description: Study of long-term survival and complications of treatment for ALL.
PubMed citation number: 12917300.

Review articles

Pui et al.

Acute lymphoblastic leukemia.
NEJM April 8, 2004; 350:1535-48.
PubMed citation number: new article not yet available.

Faderl eet al.

The biology and therapy of adult acute lymphoblastic leukemia.
Cancer Oct 1 2003; 98:1337-54.
PubMed citation number: 14508819.

Rubnitz et al.

Recent advances in the treatment and understanding of childhood acute lymphoblastic leukemia.
Cancer Treat Rev Feb 2003; 29:31-44.
PubMed citation number: 12633578

Return to Table of Contents